3.2
Impact Factor

◂ Last issue Next issue ▸ Archive Cover PDF   

Volume 16 (13); 2025

Research Papers

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
Ryan J. Sullivan, Katy K. Tsai, Anna C. Pavlick, Elizabeth I. Buchbinder, Sanjiv S. Agarwala, Antoni Ribas, Johan Jansson, Guillermo Rossiter, Anthony J. Olszanski
J. Cancer 2025; 16(13): 3797-3809. doi:10.7150/jca.117878
Full text PDF

Pseudouridylation-Related Genes Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma Patients
Chenlu Lan, Donghua Gao, Yongguang Wei, Huasheng Huang, Xianwei Lv, Xin Zhou, Wei Qin, Xiwen Liao, Guangzhi Zhu, Tao Peng
J. Cancer 2025; 16(13): 3823-3841. doi:10.7150/jca.117247
Full text PDF

Lipid-Coated Mesoporous Silica Particles for pH-Sensitive Tumor-Targeted Paclitaxel: Development, Characterization
Yingyue Deng, Tao Zhang, Jiaru Zhou, Zhihao Su, Yingsong Cao, Junxi Luo, Leming Zhao, Junjie Hua, Guoqiang Wang, Min Xiao, Junfeng Ban, Yan Zhang, Hongcai Liang
J. Cancer 2025; 16(13): 3842-3850. doi:10.7150/jca.117433
Full text PDF

Robust machine-learning based prognostic index using fatty acid metabolism genes predicts prognosis and therapy responses in glioblastoma
Erjie Zhao, Zihan Wang, Liya Tang, Longxiu Zhang, Liuguijie He, Mengdie Li, Xin Ge, Zhumei Shi, Xu Qian, Risheng Cao
J. Cancer 2025; 16(13): 3859-3873. doi:10.7150/jca.117209
Full text PDF

Prognostic significance and potential association between ALDOA and ENO1 in gastric cancer
Xuchao Wang, Yibin Lu, Zhengwu Cheng, Yizhou Yao, Xinyu Shao
J. Cancer 2025; 16(13): 3874-3883. doi:10.7150/jca.114369
Full text PDF

CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes
Peng Tang, Ruihao Zhang, Yuqi Zhang, Yuan Ao, Yanan Wang, Guannan Wang, Wenjun Wang, Junmei Xu, Fang Hu, Guangsheng Zhu
J. Cancer 2025; 16(13): 3884-3896. doi:10.7150/jca.115525
Full text PDF

Novel Tri-Specific Immuno-Modulatory Antibody Combined with HDACi to Potentiate T Cell Activation and Anti-Tumor Efficacy
Yidan Gou, Xiangfei Yuan, Dongmei Fan, Yuanyuan Yang, Hengjie Yuan
J. Cancer 2025; 16(13): 3907-3916. doi:10.7150/jca.108922
Full text PDF

Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization
Tao Pan, Jiyue Zhang, Xiaomin Wang, Yuqin Song
J. Cancer 2025; 16(13): 3917-3927. doi:10.7150/jca.115044
Full text PDF

Disulfidptosis-Associated CCNB2: A Prognostic Biomarker and Immune Microenvironment Modulator in Prostate Cancer
Wei Jiang, Qinghua Wang, Juan Zhou, Yan Zhao, Xin Qin, Xilei Li, Haopeng Li, Licheng Wang, Gang Wu
J. Cancer 2025; 16(13): 3928-3941. doi:10.7150/jca.112791
Full text PDF

Identification and validation of the PARP inhibitor-related gene KANK3 for predicting prognosis and immunotherapeutic response in prostate cancer
Yan Zhao, Qinghua Wang, Xin Qin, Wei Jiang, Haopeng Li, Mingming Xu, Xilei Li, Hanchu Ye, Juan Zhou, Xi Chen, Gang Wu
J. Cancer 2025; 16(13): 3942-3959. doi:10.7150/jca.113546
Full text PDF

SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance
Zhengyang Zhang, Xiaojie Cai, Yi Gong, Aihua Gong, Xiang Liao, Jie Gao, Dongqing Wang
J. Cancer 2025; 16(13): 3960-3971. doi:10.7150/jca.114356
Full text PDF

Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer
Zhendong Shi, Hanyan Zhu, Xiaoxing Bian, Xiaomin Qian, Jie Meng, Jin Zhang
J. Cancer 2025; 16(13): 3991-4007. doi:10.7150/jca.118908
Full text PDF

Inflammatory Bowel Disease Mediates the Causal Relationship Between Gut Microbiota and Colorectal Cancer: Identification of Therapeutic Targets and Predictive Modeling
Jin-Bei Wang, Zhen-Guo Wu, Guan-Wei Bi, Yu Li, Zhi-Wen Yao, Yan-Bo Yu
J. Cancer 2025; 16(13): 4008-4028. doi:10.7150/jca.114687
Full text PDF

Reviews

Insight into the Role of the BCL6B Gene in Biological Functions and Disease Progression
Yuqing Pan, Ya Li
J. Cancer 2025; 16(13): 3810-3822. doi:10.7150/jca.116659
Full text PDF

HKDC1 in Cancer: Mechanisms, Clinical Applications, and Future
Xia Luo, Mingjing Peng, Zhan Wang, Nayiyuan Wu, Ying Wang
J. Cancer 2025; 16(13): 3851-3858. doi:10.7150/jca.116277
Full text PDF

The Role of P53 in Immune Evasion and Therapeutic Strategies in Hematologic Malignancies
Jing Wen, Linlin Fu, Hui Zhong, Hongxia Chen
J. Cancer 2025; 16(13): 3899-3906. doi:10.7150/jca.113576
Full text PDF

Skin Cancer: Epidemiology, Screening and Clinical Features of Acral Lentiginous Melanoma (ALM), Melanoma In Situ (MIS), Nodular Melanoma (NM) and Superficial Spreading Melanoma (SSM)
Chun-Te Lu, Teng-Li Lin, Arvind Mukundan, Riya Karmakar, Anusha Chandrasekar, Wen-Yen Chang, Hsiang-Chen Wang
J. Cancer 2025; 16(13): 3972-3990. doi:10.7150/jca.116362
Full text PDF

Epigenetic alterations in triple-negative breast cancer and their clinical implications for diagnosis and therapy
Eun-Jin Go, Ji Hoon Oh
J. Cancer 2025; 16(13): 4029-4036. doi:10.7150/jca.119442
Full text PDF

Epigenetic regulation espeically histone modifications in breast cancer: A viable and emerging targeted therapeutic strategy
Yibing Zhou, Haotian Liu, Weimin Hong, Haotian Su, Yuxiao Mu, Yijie Cheng, Chaoshen Wu, Xuli Meng, Da Qian
J. Cancer 2025; 16(13): 4037-4046. doi:10.7150/jca.119306
Full text PDF

Letter

Correspondence on “Robotic radical hysterectomy for cervical cancer: current trends and controversies”
Agnieszka Rychlik, Maria Bedyńska, Denis Querleu
J. Cancer 2025; 16(13): 3897-3898. doi:10.7150/jca.114989
Full text PDF

©2025 Ivyspring International Publisher. Terms of use